The Life Sciences team advised BridgeBio Pharma (Nasdaq: BBIO) on the establishment of its joint venture with Maze Therapeutics, Contour Therapeutics, which will focus on transforming and advancing breakthrough precision medicine approaches designed to treat cardiovascular disease, the leading cause of death worldwide.
The joint venture will combine Maze’s genetically driven approach to drug discovery, as well as insights from its COMPASS platform, with BridgeBio’s expertise in cardiac drug discovery and clinical development. Together, the companies will focus on advancing genetically validated therapeutic candidates through clinical development and will initially work on the development of a treatment for patients with an undisclosed, genetically defined form of heart failure.
Founded in 2015, BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. The company’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
The Goodwin team was led by Noelle Dubiansky, Daniel Karelitz, Kimberly Maruncic and Emily Beman.
For additional details on the announcement, please read the press release and coverage by Endpoints News and FierceBiotech.